Technology strategies for practical use of biopharmaceuticals – Discussion at the review meeting in the next fiscal year

株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

【METI】
Technology strategies for practical use of biopharmaceuticals – Discussion at the review meeting in the next fiscal year
February 8th, 2021

The Ministry of Economy, Trade and Industry (METI) will establish a "review meeting for life science technology strategies" to discuss about necessary policies for practical use of biopharmaceuticals and regenerative medicine products in the next fiscal year. To enhance the competitive power of the Contract Manufacturing Organizations (CMOs)/Contract Development Manufacturing Organizations (CDMOs), their participation in this project will be promoted under the government's initiative to immediately cope with modalities and manufacturing methods of biopharmaceuticals.  The government intends to support  for biopharmaceutical CMOs/CDMOs in a particular to extend to gene/cell therapy product area that is expected to grow in the future. The strategies will be developed within the next fiscal year and then implemented as METI's policies from 2022.

(Continue to the next)

For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Singapore Pte. Ltd.